240 related articles for article (PubMed ID: 31152332)
1. Second-Generation Biomarker Testing for Irritable Bowel Syndrome Using Plasma Anti-CdtB and Anti-Vinculin Levels.
Morales W; Rezaie A; Barlow G; Pimentel M
Dig Dis Sci; 2019 Nov; 64(11):3115-3121. PubMed ID: 31152332
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects.
Pimentel M; Morales W; Rezaie A; Marsh E; Lembo A; Mirocha J; Leffler DA; Marsh Z; Weitsman S; Chua KS; Barlow GM; Bortey E; Forbes W; Yu A; Chang C
PLoS One; 2015; 10(5):e0126438. PubMed ID: 25970536
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.
Rezaie A; Park SC; Morales W; Marsh E; Lembo A; Kim JH; Weitsman S; Chua KS; Barlow GM; Pimentel M
Dig Dis Sci; 2017 Jun; 62(6):1480-1485. PubMed ID: 28451914
[TBL] [Abstract][Full Text] [Related]
4. Circulating Anti-cytolethal Distending Toxin B and Anti-vinculin Antibodies as Biomarkers in Community and Healthcare Populations With Functional Dyspepsia and Irritable Bowel Syndrome.
Talley NJ; Holtmann G; Walker MM; Burns G; Potter M; Shah A; Jones M; Koloski NA; Keely S
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00064. PubMed ID: 31356481
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiota profiles and the role of anti-CdtB and anti-vinculin antibodies in patients with functional gastrointestinal disorders (FGID).
Vasapolli R; Schulz C; Schweden M; Casèn C; Kirubakaran GT; Kirste KH; Macke L; Link A; Schütte K; Malfertheiner P
Eur J Clin Invest; 2021 Dec; 51(12):e13666. PubMed ID: 34390492
[TBL] [Abstract][Full Text] [Related]
6. Study of Antibodies to Cytolethal Distending Toxin B (CdtB) and Antibodies to Vinculin in Patients with Irritable Bowel Syndrome.
Zaki MES; Elhammady D; Foda Salama M; Abdelsalam M; Osman AOB
F1000Res; 2021; 10():303. PubMed ID: 34754418
[No Abstract] [Full Text] [Related]
7. Immunization with cytolethal distending toxin B produces autoantibodies to vinculin and small bowel bacterial changes in a rat model of postinfectious irritable bowel syndrome.
Morales W; Triantafyllou K; Parodi G; Weitsman S; Park SC; Rezaie A; Pichetshote N; Lin E; Pimentel M
Neurogastroenterol Motil; 2020 Oct; 32(10):e13875. PubMed ID: 32436301
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with the use of anti-CdtB and anti-vinculin antibodies in patients with diarrhea in Mexico.
Schmulson M; Balbuena R; Corona de Law C
Rev Gastroenterol Mex; 2016; 81(4):236-239. PubMed ID: 27681080
[TBL] [Abstract][Full Text] [Related]
9. A Predictive Model to Estimate Cost Savings of a Novel Diagnostic Blood Panel for Diagnosis of Diarrhea-predominant Irritable Bowel Syndrome.
Pimentel M; Purdy C; Magar R; Rezaie A
Clin Ther; 2016 Jul; 38(7):1638-1652.e9. PubMed ID: 27261204
[TBL] [Abstract][Full Text] [Related]
10. Cytolethal distending toxin B inoculation leads to distinct gut microtypes and IBS-D-like microRNA-mediated gene expression changes in a rodent model.
Leite G; de Freitas Germano J; Morales W; Weitsman S; Barlow GM; Parodi G; Pimentel ML; Villanueva-Millan MJ; Sanchez M; Ayyad S; Rezaie A; Mathur R; Pimentel M
Gut Microbes; 2024; 16(1):2293170. PubMed ID: 38108386
[TBL] [Abstract][Full Text] [Related]
11. Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following Campylobacter jejuni Infection in a Rat Model.
Pimentel M; Morales W; Pokkunuri V; Brikos C; Kim SM; Kim SE; Triantafyllou K; Weitsman S; Marsh Z; Marsh E; Chua KS; Srinivasan S; Barlow GM; Chang C
Dig Dis Sci; 2015 May; 60(5):1195-205. PubMed ID: 25424202
[TBL] [Abstract][Full Text] [Related]
12. No difference in serum levels of B-cell activating receptor and antibodies against cytolethal distending toxin B and flagellin in post-infectious irritable bowel syndrome and chronic fatigue syndrome after
Hanevik K; Saghaug C; Aaland M; Morch K; Langeland N
JGH Open; 2022 Mar; 6(3):185-188. PubMed ID: 35355666
[TBL] [Abstract][Full Text] [Related]
13. Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome.
Manolakis AC; Kapsoritakis AN; Georgoulias P; Tzavara C; Valotassiou V; Kapsoritaki A; Potamianos SP
BMC Gastroenterol; 2010 Oct; 10():118. PubMed ID: 20946669
[TBL] [Abstract][Full Text] [Related]
14. Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients.
Rana SV; Sharma S; Sinha SK; Parsad KK; Malik A; Singh K
Trop Gastroenterol; 2012; 33(4):251-6. PubMed ID: 23923350
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 5-hydroxytryptophan signaling pathway characteristics in diarrhea-predominant irritable bowel syndrome and ulcerative colitis.
Yu FY; Huang SG; Zhang HY; Ye H; Chi HG; Zou Y; Lv RX; Zheng XB
World J Gastroenterol; 2016 Mar; 22(12):3451-9. PubMed ID: 27022227
[TBL] [Abstract][Full Text] [Related]
16. AGA Technical Review on the Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D).
Carrasco-Labra A; Lytvyn L; Falck-Ytter Y; Surawicz CM; Chey WD
Gastroenterology; 2019 Sep; 157(3):859-880. PubMed ID: 31351880
[TBL] [Abstract][Full Text] [Related]
17. Carriage of CdtB Encoding Campylobacter spp., Salmonella enterica, and Yersinia entercolitica in Patients with Gastroenteritis and Irritable Bowel Syndrome.
Ganji L; Shirazi MH; Ebrahimi-Daryani N; Eslami P; Rahbar M; Zali MR; Alebouyeh M
Dig Dis Sci; 2022 Dec; 67(12):5522-5528. PubMed ID: 35357609
[TBL] [Abstract][Full Text] [Related]
18. α2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease.
Manolakis AC; Christodoulidis G; Kapsoritakis AN; Georgoulias P; Tiaka EK; Oikonomou K; Valotassiou VJ; Potamianos SP
World J Gastroenterol; 2017 Jan; 23(3):437-446. PubMed ID: 28210079
[TBL] [Abstract][Full Text] [Related]
19. A definitive blood test for post-infectious irritable bowel syndrome?
Barlow GM; Rezaie A; Lin E; Pimentel M
Expert Rev Gastroenterol Hepatol; 2016 Nov; 10(11):1197-1199. PubMed ID: 27682513
[No Abstract] [Full Text] [Related]
20. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies.
Schoepfer AM; Trummler M; Seeholzer P; Seibold-Schmid B; Seibold F
Inflamm Bowel Dis; 2008 Jan; 14(1):32-9. PubMed ID: 17924558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
